Cargando…

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease

Extramedullary multiple myeloma (EMD) is an aggressive subentity of multiple myeloma (MM) with poor prognosis. As more innovative therapeutic approaches are needed for the treatment of MM with EMD, we conducted this multicenter, non-randomized phase II trial of daratumumab in combination with dexame...

Descripción completa

Detalles Bibliográficos
Autores principales:	Byun, Ja Min, Min, Chang-Ki, Kim, Kihyun, Bang, Soo-Mee, Lee, Je-Jung, Kim, Jin Seok, Yoon, Sung-Soo, Koh, Youngil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9590218/ https://www.ncbi.nlm.nih.gov/pubmed/36274163 http://dx.doi.org/10.1186/s13045-022-01374-5

Ejemplares similares

P894: A PHASE II TRIAL TO EVALUATE THE EFFICACY OF DARATUMUMAB WITH DCEP IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH EXTRAMEDULLARY DISEASE AFTER BORTEZOMIB BASED TREATMENT
por: Byun, J. M., et al.
Publicado: (2022)

Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea
por: Kim, Hyo Jung, et al.
Publicado: (2015)

Daratumumab monotherapy in relapsed and refractory multiple myeloma patients with severely compromised forced expiratory volume in one second
por: Kim, Jin-Hyo, et al.
Publicado: (2022)

Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?
por: Park, Hyunkyung, et al.
Publicado: (2020)

Daratumumab efficacy in extramedullary orbital myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX
por: Kaufman, Jonathan L., et al.
Publicado: (2020)

Advantage of achieving deep response following frontline daratumumab-VTd compared to VRd in transplant-eligible multiple myeloma: multicenter study
por: Byun, Ja Min, et al.
Publicado: (2023)

Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
por: Gasparetto, Cristina, et al.
Publicado: (2020)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Predictive role of absolute lymphocyte count in daratumumab-treated patients with relapsed/refractory multiple myeloma
por: Cho, Hee Jeong, et al.
Publicado: (2023)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
por: Dimopoulos, Meletios A., et al.
Publicado: (2018)

Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party
por: Kim, Seok Jin, et al.
Publicado: (2016)

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
por: Siegel, David S., et al.
Publicado: (2020)

Role of Daratumumab in Combination With Standard Therapies in Patients With Relapsed and Refractory Multiple Myeloma
por: Bapatla, Anusha, et al.
Publicado: (2021)

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2021)

Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
por: Moreau, Philippe, et al.
Publicado: (2023)

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
por: Weisel, Katja, et al.
Publicado: (2020)

P1157: PHASE II STUDY OF GLOFITAMAB, POSELTINIB AND LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE B CELL LYMPHOMAS
por: Min Byun, Ja, et al.
Publicado: (2023)

Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP‐164 study)
por: Lee, Ho Sup, et al.
Publicado: (2020)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
por: Offidani, Massimo, et al.
Publicado: (2021)

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2023)

P976: REAL-WORLD OUTCOMES OF PATIENTS WITH PENTA-EXPOSED MULTIPLE MYELOMA WHO WERE TREATED WITH SELINEXOR AND DEXAMETHASONE: KOREAN MULTICENTER RETROSPECTIVE ANALYSIS
por: Ho Yi, Jun, et al.
Publicado: (2023)

Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
por: Spencer, Andrew, et al.
Publicado: (2018)

A Pilot Study of Bortezomib in Korean Patients with Relapsed or Refractory Myeloma
por: Lee, Keun-Wook, et al.
Publicado: (2005)

Highly Expressed Integrin-α8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse
por: Ryu, Jiyeon, et al.
Publicado: (2016)

Multiple myeloma with huge extramedullary plasmacytomas
por: Bae, Soo-Young, et al.
Publicado: (2010)

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
por: Yan, Xiaoyu, et al.
Publicado: (2017)

Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
por: Xu, XS, et al.
Publicado: (2017)

Daratumumab as Single Agent in Relapsed/Refractory Myeloma Patients: A Retrospective Real-Life Survey
por: Markovic, Uros, et al.
Publicado: (2021)

Laboratory features of tumour lysis syndrome following daratumumab monotherapy in relapsed/refractory multiple myeloma
por: Shackleton, Louisa, et al.
Publicado: (2020)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study “REBUILD”
por: Terpos, Evangelos, et al.
Publicado: (2022)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
por: Fucci, Ludovica, et al.
Publicado: (2022)

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
por: Tauseef, Abubakar, et al.
Publicado: (2022)

Daratumumab with lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients – real world evidence analysis
por: Stork, Martin, et al.
Publicado: (2023)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study
por: Kwon, Jihyun, et al.
Publicado: (2016)

Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study
por: Suzuki, Kenshi, et al.
Publicado: (2018)

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma
por: Chari, Ajai, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_hghsjdcjd0254emrbi90asksjk